RANI - Rani Therapeutics begins phase 1 trial of oral hormone drug RT-102 for bone disorder

Rani Therapeutics (NASDAQ:RANI) began a phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34), to treat osteoporosis, delivered via RaniPill capsule. Osteoporosis is a disorder that causes bones to become weak and brittle. PTH is one of the treatments. The company said current forms of PTH(1-34) require daily self-injections. The company said the first person was administered RT-102 in the phase 1 trial, which is being conducted in Australia in healthy adult women volunteers.

For further details see:

Rani Therapeutics begins phase 1 trial of oral hormone drug RT-102 for bone disorder